Curated News
By: NewsRamp Editorial Staff
June 18, 2025
HeartBeam Strengthens Cardiac Care Innovation with New Patents
TLDR
- HeartBeam's new patents enhance its competitive edge in remote cardiac diagnostics, offering a unique 3D ECG device and rhythm analysis algorithm for precise arrhythmia detection.
- HeartBeam's 3D ECG device collects high-fidelity signals in three directions for on-demand symptom recording, with its rhythm algorithm enhancing diagnostic precision across monitoring systems.
- HeartBeam's innovations in cardiac care technology promise to improve patient outcomes by enabling accurate, remote heart monitoring and timely medical intervention.
- HeartBeam is revolutionizing cardiac care with a cable-free 3D ECG device and AI-enhanced diagnostics, aiming to make heart health management accessible anywhere.
Impact - Why it Matters
This news is significant as it highlights HeartBeam's advancements in remote cardiac diagnostics, offering a glimpse into the future of healthcare where critical cardiac insights can be obtained outside traditional medical settings. The development of a cable-free 3D ECG device and rhythm analysis algorithm represents a leap forward in making cardiac care more accessible and efficient, potentially saving lives by enabling early detection and intervention for arrhythmias and other heart conditions. The integration of AI promises to further enhance diagnostic accuracy, underscoring the importance of HeartBeam's innovations in improving patient outcomes and transforming cardiac health management.
Summary
HeartBeam Inc. (NASDAQ: BEAT), a pioneering medical technology company, has recently bolstered its intellectual property portfolio with the issuance of two new U.S. patents. These patents cover the innovative technologies behind HeartBeam's compact, cable-free 3D ECG device and its advanced rhythm analysis algorithm. The device, designed for on-demand symptom recording and 12-lead ECG synthesis, utilizes chest and finger electrodes to capture high-fidelity signals in three dimensions, offering a breakthrough in remote cardiac diagnostics. Currently under FDA review, the device's software is supported by data from the VALID-ECG pivotal study. With a total of 20 issued patents and 34 additional filings, HeartBeam is leading the charge in digital cardiac care innovation, with plans to integrate AI for even greater diagnostic accuracy. For more details, visit the full press release.
HeartBeam's mission is to revolutionize cardiac care by enabling powerful cardiac insights anywhere, anytime. Their platform technology, the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, is set to redefine cardiac health management outside traditional medical facilities. With 13 U.S. and 4 international patents, HeartBeam is at the forefront of transforming how cardiac conditions are diagnosed and managed. Learn more about their groundbreaking work at www.HeartBeam.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Strengthens Cardiac Care Innovation with New Patents
